US HB4597 | 2019-2020 | 116th Congress

US Congress House Bill 4597 (Prior Session Legislation)

Status

Sponsorship: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on October 1 2019 - 25% progression, died in committee
Action: 2019-10-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

Title

ACCESS for Biosimilars Act of 2019 Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019

History

Date	Chamber	Action
2019-10-02	House	Referred to the Subcommittee on Health.
2019-10-01	House	Referred to the Subcommittee on Health.
2019-10-01	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-10-01	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-10-01	House	Introduced in House